Docetaxel
Gastroesophageal Junction Adenocarcinoma
Explore 110 assets in Gastroesophageal Junction Adenocarcinoma →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Kyowa Kirin Co., Ltd.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06266299CT.gov A Study of KK2269 in Adult Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT04895709CT.gov A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT04882241CT.gov Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | — | Completed | — | — | — |
NCT04276493CT.gov Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | — | Completed | — | — | — |
NCT03221426CT.gov Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | — | Completed | — | — | — |
NCT03933449CT.gov Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study | — | Completed | — | — | — |
NCT02564263CT.gov Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastroesophageal Junction Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | Kyowa Kirin Co., Ltd. | P3 | BB · 66 |
| Irinotecan | AstraZeneca | P3 | BBB |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Pembrolizumab | Eikon Therapeutics | P3 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P3 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Oxaliplatin | Alliance for Clinical Trials in Oncology | P3 | BB |
| Levofolinic Acid | Merck Sharp & Dohme LLC | P3 | BB |
| Disitamab Vedotin | BeOne Medicines | P2 | BB |
+42 more in the Gastroesophageal Junction Adenocarcinoma cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Pancreatic Adenocarcinoma | — | P2 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Gastroesophageal Junction Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docetaxel-gastroesophageal-junction-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →